Pro-Dex, Inc.Pro-Dex, Inc. Announces Fiscal 2023 Second Quarter and Six-Month Results

02 Feb 2023
www.biospace.com
Financial Statement
IRVINE, CA / ACCESSWIRE / February 2, 2023 / Pro-Dex, Inc. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 second quarter ended December 31, 2022. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2023 with the Securities and Exchange Commission today. Quarter Ended December 31, 2022 Net sales for the three months ended December 31, 2022 increased $1.1 million, or 11%, to $11.3 million from $10.2 million for the three months ended December 31, 2021, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer coupled with increased repair revenue of that same handpiece. Gross profit for the three months ended December 31, 2022 decreased $781,000, or 23%, to $2.6 million from $3.4 million for the same period in fiscal 2022, due to continuing price increases for components, especially chips for our printed circuit board assemblies, as well higher repair costs for the surgical handpiece that we sell to our largest customer. As previously disclosed, beginning in fiscal 2023 and continuing through the end of the second quarter of fiscal 2023, we began implementing a customer upgrade request for our largest customer. We have proceeded in good faith to upgrade all units returned for repair to the newest release of the handpiece while we continue to negotiate with this customer to obtain additional compensation for these more costly upgraded repairs. Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2022 decreased $316,000, or 18%, to $1.5 million compared to $1.8 million in the prior fiscal year's corresponding quarter, reflecting in part the higher number of billable engineering projects in the current fiscal quarter compared to the same period in the prior fiscal year and reduced general and administrative expenses mostly due to declining non-cash stock compensation expense. Net income for the quarter ended December 31, 2022 was $879,000, or $0.24 per diluted share, compared to $925,000, or $0.25 per diluted share, for the corresponding quarter in fiscal 2022. Six Months Ended December 31, 2022 Net sales for the six months ended December 31, 2022 increased $2.2 million, or 11%, to $22.4 million from $20.2 million for the six months ended December 31, 2021, due primarily to increased repair revenue from the orthopedic surgical handpiece that we sell to our largest customer and increased non-recurring engineering and proto-type revenue. Gross profitfor the six months ended December 31, 2022decreased $1.3 million, or 18%, compared to the same period in fiscal 2022 due to the increased costs incurred in the repairs of the surgical handpiece we sell to our largest customer as described above, continuing component price increases, and higher cost structures in our machine shop, assembly, materials, and quality departments. Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2022 decreased $420,000, or 11%, to $3.5 million compared to $3.9 million in the prior fiscal year's corresponding period. Net income for the six months ended December 31, 2022 and 2021 remained flat at $2.0 million, or $0.53 per diluted share. CEO Comments Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our second quarter and year-to-date results especially considering the challenging environment facing businesses today." Mr. Van Kirk continued, "We are excited to begin operations in the Franklin facility this fiscal quarter and we remain positive that the building will allow for our continued expected growth." About Pro-Dex, Inc.Pro-Dex, Inc.: Pro-Dex, Inc.Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex, Inc.Pro-Dex, Inc. also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at . Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance (including, but not limited to, the anticipated commencement of operations in the Franklin facility and expected future growth), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission. (tables follow) PRO-DEX, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share amounts) December 31, 2022 June 30, 2022 ASSETS Current assets: Cash and cash equivalents $ 382 $ 849 Investments 1,134 755 Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at December 31, 2022 and at June 30, 2022, respectively 12,195 15,384 Deferred costs 877 710 Inventory 15,135 12,678 Prepaid expenses and other current assets 1,664 790 Total current assets 31,387 31,166 Land and building, net 6,296 6,343 Equipment and leasehold improvements, net. 5,203 4,833 Right-of-use asset, net 2,063 2,248 Intangibles, net 98 118 Deferred income taxes, net 764 797 Investments 1,726 1,779 Other assets 42 42 Total assets $ 47,579 $ 47,326 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,364 $ 3,761 Accrued expenses 3,314 2,751 Income taxes payable 1,026 544 Deferred revenue 851 1,013 Notes payable 3,110 3,285 Total current liabilities 11,665 11,354 Lease liability, net of current portion 1,850 2,054 Notes payable, net of current portion 9,590 10,250 Total non-current liabilities 11,440 12,304 Total liabilities 23,105 23,658 Shareholders' equity: Common shares; no par value; 50,000,000 shares authorized; 3,553,929 and 3,596,131 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively 6,533 7,682 Retained earnings 17,941 15,986 Total shareholders' equity 24,474 23,668 Total liabilities and shareholders' equity $ 47,579 $ 47,326 PRO-DEX, INC.PRO-DEX, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts) Three Months Ended December 31, Six Months Ended December 31, 2022 2021 2022 2021 Net sales $ 11,282 $ 10,173 $ 22,369 $ 20,161 Cost of sales 8,659 6,769 16,791 13,329 Gross profit 2,623 3,404 5,578 6,832 Operating expenses: Selling expenses 68 22 122 59 General and administrative expenses 951 1,165 1,975 2,257 Research and development costs 467 615 1,395 1,596 Total operating expenses 1,486 1,802 3,492 3,912 Operating income 1,137 1,602 2,086 2,920 Interest expense (128 ) (117 ) (258 ) (237 ) Unrealized gain (loss) on marketable equity investments 158 (300 ) 408 (152 ) Interest and other income 7 25 225 49 Gain on sale of investments - - 7 - Income before income taxes 1,174 1,210 2,468 2,580 Income tax expense (295 ) (285 ) (513 ) (592 ) Net income $ 879 $ 925 $ 1,955 $ 1,988 Basic net income per share: Net income $ 0.25 $ 0.25 $ 0.54 $ 0.54 Diluted net income per share: Net income $ 0.24 $ 0.25 $ 0.53 $ 0.53 Weighted average common shares outstanding: Basic 3,574 3,657 3,595 3,654 Diluted 3,652 3,767 3,672 3,774 Common shares outstanding 3,554 3,642 3,554 3,642 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 SOURCE: Pro-Dex, Inc. View source version on accesswire.com:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.